Atad J, Hallak M, Auslender R, Porat-Packer T, Zarfati D, Abramovici H
Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
Obstet Gynecol. 1996 Feb;87(2):223-7. doi: 10.1016/0029-7844(95)00389-4.
To compare the efficacy of three methods for ripening and dilating the unfavorable cervix for induction of labor.
Pregnant women having an indication for induction of labor with a singleton vertex fetus, intact membranes, and Bishop score of no more than 4 were randomized to one of three induction methods: intravaginal prostaglandin (PG) E2 tablets (3 mg) followed by a second dose if labor did not start; continuous intravenous oxytocin drip; or the Atad Ripener Device, with inflation of both balloons and removal after 12 hours. For all patients, the cervix was assessed by the same investigator before induction and 12 hours later.
Thirty subjects were included in the PGE2 group, 30 in the oxytocin group, and 35 in the Atad Ripener Device group. The postpartum course was comparable in all. The change in Bishop score in the PGE2 and Atad Ripener Device groups was significantly better than in the oxytocin group (median and range of 5[0-9] and 5[0-7], respectively, versus 2.5 [0-9]; P < .01). Cervical dilation more than 3 cm was more frequent in the Atad Ripener Device group compared with both the PGE2 and oxytocin groups (85.7 versus 50 and 23.3%, respectively; P < .01). The trial of induction failed in only two patients (5.7%) in the Atad Ripener Device group, compared with six (20%) in the PGE2 and 16 (53.3%) in the oxytocin groups (P < .001). Mean (+/- standard deviation) induction-to-delivery interval was 21.3 +/- 7.0 hours in the Atad Ripener Device group, 23.2 +/- 12.5 hours in the PGE2 group, and 28.2 +/- 14.7 hours in the oxytocin group. The success rate for vaginal delivery was significantly better in the Atad Ripener Device and PGE2 groups compared with the oxytocin group (77.1 and 70%, respectively, versus 26.7%; P < .01).
The Atad Ripener Device had a significantly better success rate for cervical dilation and a lower failure rate than those for PGE2 and oxytocin. The PGE2 and Atad Ripener Device groups had better results than the oxytocin group in regard to Bishop score change and induction-to-delivery interval. The Atad Ripener Device may be a superior method for cervical ripening and labor induction in patients with unfavorable cervices.
比较三种用于引产时软化和扩张宫颈条件不佳的方法的疗效。
有引产指征、单胎头位、胎膜完整且 Bishop 评分不超过 4 分的孕妇被随机分为三种引产方法之一:阴道内放置前列腺素(PG)E2 片(3 毫克),若未发动宫缩则给予第二剂;持续静脉滴注缩宫素;或使用 Atad 促宫颈成熟装置,两个球囊充气,12 小时后取出。对于所有患者,在引产开始前和 12 小时后由同一名研究者评估宫颈情况。
PGE2 组纳入 30 名受试者,缩宫素组 30 名,Atad 促宫颈成熟装置组 35 名。所有组产后过程相似。PGE2 组和 Atad 促宫颈成熟装置组 Bishop 评分的变化明显优于缩宫素组(中位数及范围分别为 5[0 - 9]和 5[0 - 7],而缩宫素组为 2.5[0 - 9];P < 0.01)。与 PGE2 组和缩宫素组相比,Atad 促宫颈成熟装置组宫颈扩张超过 3 厘米的情况更常见(分别为 85.7%、50%和 23.3%;P < 0.01)。Atad 促宫颈成熟装置组仅有两名患者(5.7%)引产失败,而 PGE2 组有 6 名(20%),缩宫素组有 16 名(53.3%)(P < 0.001)。Atad 促宫颈成熟装置组引产至分娩的平均(±标准差)间隔时间为 21.3 ± 7.0 小时;PGE2 组为 23.2 ± 12.5 小时;缩宫素组为 28.2 ± 14.7 小时。与缩宫素组相比,Atad 促宫颈成熟装置组和 PGE2 组阴道分娩成功率明显更高(分别为 77.1%和 70%,而缩宫素组为 26.7%;P < 0.01)。
与 PGE2 和缩宫素相比时,Atad 促宫颈成熟装置在宫颈扩张成功率方面明显更高,失败率更低。在 Bishop 评分变化和引产至分娩间隔时间方面 PGE2 和 Atad 促宫颈成熟装置组比缩宫素组结果更好。对于宫颈条件不佳患者,Atad 促宫颈成熟装置可能是宫颈成熟和引产的一种更优方法。